Autopsy report · NCT03478904

Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer

“Study drug is now commercially available in tablet format”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years before it started.
• Ran for about 9 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Prostate Cancer

Interventions

Enzalutamide Liquid; Enzalutamide Capsule

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• P1101 in Treating Patients With Myelofibrosis
  “Study drug became commercially available” (86% match in meaning)
• A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
  “One of the drugs for the study is not commercially available.” (75% match in meaning)
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (71% match in meaning)
• Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
  “No study drug available. Same concept with new study drug will be explored in M19TGA study” (70% match in meaning)
• Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
  “study drug unavailable” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.